NCT07107750View on ClinicalTrials.gov

CA-4948 in Combination With Cisplatin, Gemcitabine, and Durvalumab in Patients With Untreated Advanced or Metastatic Biliary Tract Cancer

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

48

Participants

Timeline

Start Date

October 31, 2025

Primary Completion Date

January 31, 2030

Study Completion Date

December 31, 2031

Conditions
Metastatic Biliary Tract CancerMetastatic Biliary Tract Carcinoma
Interventions
DRUG

CA-4948

Provided by Curis.

DRUG

Gemcitabine

Standard of care.

DRUG

Cisplatin

Standard of care.

BIOLOGICAL

Durvalumab

Standard of care.

Trial Locations (1)

63110

Washington University School of Medicine, St Louis

All Listed Sponsors
collaborator

Curis, Inc.

INDUSTRY

collaborator

Washington University Siteman Cancer Center

OTHER

lead

Washington University School of Medicine

OTHER